Smart Money is Flowing Into Jazz Pharmaceuticals plc (JAZZ)

As industrywide interest jumped, key money managers were breaking ground themselves. Ardsley Partners, managed by Philip Hempleman, established the most outsized position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ), of call options underlying JAZZ shares. Ardsley Partners had $6.6 million invested in the position at the end of the quarter. Peter Muller’s PDT Partners also initiated a $5 million position during the quarter. The other funds with brand new JAZZ positions are Matthew Hulsizer’s PEAK6 Capital Management, George Hall’s Clinton Group, and Steve Cohen’s Point72 Asset Management.

Let’s now review hedge fund activity in other stocks similar to Jazz Pharmaceuticals plc (NASDAQ:JAZZ). We will take a look at Towers Watson & Co (NYSE:TW), JetBlue Airways Corporation (NASDAQ:JBLU), SCANA Corporation (NYSE:SCG), and Green Mountain Coffee Roasters Inc. (NASDAQ:GMCR). All of these stocks’ market caps resemble JAZZ’s market cap.

As you can see these stocks had an average of 26.75 hedge funds with bullish positions and the average amount invested in these stocks was $620 million. That figure was $483 million in JAZZ’s case. JetBlue Airways Corporation (NASDAQ:JBLU) is the most popular stock in this table. On the other hand SCANA Corporation (NYSE:SCG) is the least popular one with only 12 bullish hedge fund positions. Compared to these stocks Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.